

Rec 6

APR 14 2000

jb

# **Building Effective Partnerships FDA Public Meeting**

## **Panelist Biographies**

Jane Henney  
Robert Buchanan  
Victoria Durant-Gonzalez  
David Feigel  
Jesse Goodman  
David Lineback  
John Marzilli  
Tobias Massa  
Bert Mitchell  
Bernard Schwetz  
Linda Suydam  
Janet Woodcock

00N-0001

REF 2

**JANE E. HENNEY, M.D.**  
**Commissioner of Food and Drugs**  
**Food and Drug Administration**

Dr. Henney began her tenure as Commissioner of the Food and Drug Administration (FDA) in November of 1998. Prior to that, she served as the first Vice President of the University of New Mexico Health Sciences Center from 1994 to 1998. Before joining the University, Dr. Henney served as the Deputy Commissioner for Operations at FDA from 1992 to 1994. Dr. Henney's other past academic administrative positions have included Vice Chancellor for Health Programs and Policy at the University of Kansas, and Acting Director of the University of Kansas Mid America Cancer Center from 1985 to 1992. She also served as Interim Dean of the School of Medicine at the University of Kansas from 1987 to 1989. From 1976 to 1985, Dr. Henney held various positions at the National Cancer Institute (NCI) of the National Institutes of Health. From 1980-1985, Dr. Henney was Deputy Director of the NCI.

In addition to being an active member of many professional societies, Dr. Henney has been the President of the United States Pharmacopeial Convention, a member of the Advisory Committee to the Director for the National Institutes of Health, a member of the National Advisory Research Resources Council, and a member of the American Cancer Society National Board of Directors. She has served as a member of the Board of Directors of the Lovelace Respiratory Institute, the Kansas Health Foundation, and the Kansas State University Cancer Center. Dr. Henney also has served on an Advisory Committee for The Commonwealth Fund and as a consultant to the W.K. Kellogg Foundation. She has also served as a member of the Board of Trustees at Manchester College.

Dr. Henney is a graduate of Indiana University School of Medicine and Manchester College. She completed her medical internship at St. Vincent's Hospital, and her residency at Georgia Baptist Hospital. Dr. Henney was a Fellow in Medical Oncology at M.D. Anderson Hospital and Tumor Institute, and completed graduate medical work at the Cancer Therapy Evaluation Program at NCI. She has also completed management training at the John F. Kennedy School of Government at Harvard University.

In addition to other distinguished honors, Dr. Henney was recently given an Honorary Fellowship from the American College of Healthcare Executives. She also received the Indiana University Medical School Distinguished Alumni Award in 1998, the Manchester College Alumni Award in 1996, the M.D. Anderson Cancer Center Distinguished Alumnus Award, and was a member of the Leadership New Mexico Inaugural Class in 1996-1997. Dr. Henney received the Public Health Service Commendation Medal in 1979 and 1981, and the Commissioner's Special Citation in 1994. Dr. Henney has also received the Jacobs Institute's Excellence in Women's Health Award, the Public Health Leadership Award from the National Organization for Rare Disorders, and the George Crile Award from the International Platform Association.

**ROBERT L. BUCHANAN, PH.D.**  
**Senior Science Advisor**  
**Center for Food Safety and Applied Nutrition**  
**U.S. Food and Drug Administration**

After receiving his B.S., M.S., M.Phil., and Ph.D. degrees in Food Science from Rutgers University and post-doctoral training in mycotoxicology at the University of Georgia, Dr. Buchanan has spent the past 25 years teaching and conducting research in food safety, first in academia, then with the USDA Agricultural Research Service, and most recently as the Lead Scientist for the FDA Food Safety Initiative. His scientific interests are diverse, and include extensive experience in predictive microbiology, quantitative microbial risk assessment, microbial physiology, mycotoxicology, and HACCP systems. He also has an ongoing interest in the

development of science-based public health policy; in addition to currently serving as the FDA CFSAN Senior Science Advisor, he also served as Deputy Administrator for Science with the USDA Food Safety & Inspection Service. Dr. Buchanan is a member of the National Advisory Committee on Microbiological Criteria for Foods and the International Commission for Microbiological Specifications for Foods, was a member of the National Academy of Sciences' Institute of Medicine Committee on Emerging Microbial Threats, and is on the editorial boards of several journals. He has published approximately 300 manuscripts, book chapters, and abstracts on a wide range of subjects related to food safety, and is one of the co-developers of the widely used USDA Pathogen Modeling Program.

**VICTORIA DURANT-GONZALEZ, Ph.D.**  
**Director of Community Service**  
**Spelman College**

Dr. Durant-Gonzalez is the Director of Community Service at Spelman College and is responsible for providing community service opportunities for over 1800 students and service learning opportunities for the faculty. She has developed the Harris Homes First Grade Initiative Partnership and the foundation for the Johnnetta B. Cole Institute for Community Service and Community Building (JBCI). From 1992 - 1996, Dr. Durant-Gonzalez served as the Cluster Coordinator and Cluster Support Facilitator Coordinator for the Atlanta Project, targeting specific community organizations to ensure their support and participation, and securing the award of a 1.2 million-dollar grant from the State of Georgia. She also taught African-American Anthropology, Anthropology of Development, Cross-Cultural Sex Stratification, Community Development and Urban Anthropology, from 1991-1992, as an Assistant Professor at Georgia State University.

In addition, Dr. Durant-Gonzalez has been an active participant in community service, Programs in Public Housing Communities, designing and implementing a family art book program and a photography program for public housing families on behalf of NEXUS Contemporary Art Center. She has also published several articles and reports.

**DAVID W. FEIGAL, Jr., M.D., M.P.H.**  
**Director, Center for Devices and Radiological Health**  
**Food and Drug Administration**

Dr. Feigal is a native Minnesotan whose education includes a B.S. from the University of Minnesota and M.D. from Stanford University Medical School and a M.P.H. from the University of California Berkeley. He did his Internal Medicine residency training at the University of California at Davis Medical Center and a fellowship in Clinical Epidemiology at the University of California at San Francisco. He joined the UCSF School of Medicine faculty in 1984 with joint appointments in the Departments of Medicine, and Epidemiology and Biostatistics. In 1989 he moved to the Department of Medicine at the University of California, San Diego.

He came to the Food and Drug Administration in 1992 to head the Division of Anti-viral drug products, a position he held until 1997. In 1996 he was also the acting Division Director of the Anti-Infective Drug Division. From 1994 to 1997 he was been the Director of the Office of Drug Evaluation IV. In the Fall of 1997, he moved to the Center for Biologics Research and Evaluation as the Medical Deputy Director. In the Spring of 1999, the Commissioner of the FDA appointed Dr. Feigal as the Director for the Center for Devices and Radiological Health. He has been a member of a number of committees and panels sponsored by the World Health Organization, National Institutes of Health, the Institute of Medicine, and the Centers for Disease Control. He has represented the FDA in the International Conference on Harmonization, the Tripartite Meetings, and at many regulatory meetings.

**JESSE L. GOODMAN, M.D., M.P.H.**  
**Acting Deputy Director**  
**Center for Biologics Evaluation and Research**  
**Food and Drug Administration**

Dr. Goodman became Acting Deputy Director (Medicine) of the Center for Biologics Evaluation and Research (CBER) in 1999. CBER is the FDA Center responsible for blood and related products, vaccines and cellular and tissue therapies (including gene therapy) and Dr. Goodman plays an active role in medical and public health oversight of activities in all of these areas, including interactions with other agencies and the public. He came to the FDA's Office of the Commissioner in late 1998 from the University of Minnesota where he first joined the Faculty in 1985 and most recently served as Professor of Medicine and as Director of the Division of Infectious Diseases (currently on leave). A graduate of Harvard College, he received his M.D. at Albert Einstein, did residency and Fellowship training at the Hospital of the University of Pennsylvania and at UCLA (where he was also Chief Medical Resident), and is Board Certified in Internal Medicine, Oncology and Infectious Diseases. He trained in the virology laboratory of Jack Stevens at UCLA and has had an active laboratory program and numerous publications in the pathogenesis of infectious diseases, in particular tick-borne infections. His laboratory in Minnesota, with support from NIH, isolated the etiologic agent of human granulocytic ehrlichiosis (HGE) and, more recently, has characterized the basic events involved in the infection of leukocytes, including its cellular receptor. He has been an active clinician, clinical investigator, administrator and educator in the academic setting. With support from the Bush Foundation, Dr. Goodman obtained a MPH in Environmental Health at the University of Minnesota and is interested in improving public health through science-based policy and communication. At FDA, he helped originate and co-chaired both the FDA Task Force and the U.S. Government Interagency Task Force on Antimicrobial Resistance.

**DAVID R. LINEBACK, PH.D.**  
**Director**  
**Joint Institute for Food Safety and Applied Nutrition**  
**University of Maryland at College Park**

Dr. David R. Lineback, Director, Joint Institute for Food Safety and Applied Nutrition (JIFSAN), University of Maryland at College Park is a carbohydrate chemist and food scientist with an extensive academic background. Before going to Maryland, he was Dean, College of Agriculture at the University of Idaho (1993-1998). He has held academic appointments at North Carolina State University, the Pennsylvania State University, Kansas State University, and the University of Nebraska. He was head of the Department of Food Science at North Carolina State University (1980-1993) and at Pennsylvania State University (1976-1980).

Long active in the American Association of Cereal Chemists (AACC) and the Institute of Food Technologists (IFT), Dr. Lineback served as president of the Institute in 1992-93 and chaired a number of its committees and two regional sections. He served as president of the AACC in 1983-84. He has been a voting member of the Food and Drug Administration's Food Advisory Committee 1991-95, 97-; President-elect 1997-98; President 1998-99. He is a member of the Governing Council of the International Union of Food Science and Technology (1999-) and chairs its Scientific Council (1999-). In 1997 he served as chair of the Joint FAO/WHO Expert Consultant on Carbohydrates in Human Nutrition in Rome. He serves as a scientific advisor to the Food, Nutrition, and Safety Committee of the International Life Sciences Institute (ILSI) - North America. Dr. Lineback has served as Food Update (Board of Governors, 1986-94, 1999-), Starch Round Table (Board of Directors, 1983-), Food Processors Institute (Board of Trustees, 1987-93), and Wheat Industry Council (Regional Advisor, 1982-86). The recipient of several awards, Dr. Lineback earned a B.S. degree in chemistry from Purdue University and a Ph.D. (carbohydrate chemistry) from the Ohio State University.

**JOHN R. MARZILLI**  
**Deputy Associate Commissioner for Regulatory Affairs**  
**Food and Drug Administration**

Mr. Marzilli currently serves as the Deputy Associate Commissioner for Regulatory Affairs having the responsibility of assisting the Associate Commissioner for Regulatory Affairs with the direction and coordination of compliance activities of the FDA.

He was born in Newton, Massachusetts and following graduation from Newton High School, Mr. Marzilli attended Northeastern University where he received his B.S. Degree in Chemistry in 1975. Subsequent to participating in Northeastern University's Co-op as a Chemist in the FDA Boston District Office, he was hired as an Analytical Chemist - a position he held from 1975 to 1986. In 1986, he was promoted to Scientific Coordinator and transferred to the Division of Field Science in FDA Headquarters, Rockville, Maryland. In October 1989, he accepted a position as Consumer Safety Officer with the FDA's Division of Federal-State Relations. In March 1993, Mr. Marzilli was selected to participate in the Executive Potential Program. This 12 month program, which is under the direction of the U.S. Office of Personnel Management, provides training and development experiences to prepare individuals for executive positions in the federal government. In April 1994, he accepted a position as Deputy Director, Division of Field Science. As Deputy, he served as a focal point in all laboratory functions of the FDA field laboratories. In June 1995, Mr. Marzilli was officially appointed as the Director of FDA's Cincinnati District Office having responsibility for all agency activities within the states of Ohio and Kentucky. In August 1997, Mr. Marzilli was appointed to serve as the Director of FDA's New England states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. In January 2000, Mr. Marzilli was appointed to his current position as the Deputy Associate Commissioner for Regulatory Affairs.

**TOBIAS MASSA, PH.D., DABT**  
**Executive Director**  
**Global Regulatory Affairs**  
**Eli Lilly and Company**

Tobias Massa, Ph.D., DABT is the Executive Director of Global Regulatory Affairs and is responsible for all regulatory aspects of chemistry, manufacturing and controls for all Eli Lilly products, as well as submission coordination, labeling and medical information. He chairs the Corporate Specifications and Regulatory Information Technology Committees and is a member of the Regulatory/ Quality, New Product Launch, Development-Manufacturing Strategy, Clinical Research and Global Product Labeling Committees. He also is a member of the Continuing Legal Education implementation team, and the Global Development Quality Steering Committee.

Dr. Massa was a toxicologist at the Schering Plough Research Institute from 1978 to 1986 and was Associate Director/Group Leader in Toxicology for Pfizer from 1986 to 1990. He rejoined Schering Plough as Associate Director of Regulatory Affairs in 1990 and was most recently Senior Director of Worldwide Regulatory Affairs (Chemistry/Manufacturing/Controls) prior to joining Lilly as Director of Global Regulatory Affairs in 1998. Dr. Massa is currently chair of the Biology and Biotechnology Committee, and member of the FDAMA implementation team of the Pharmaceutical Research and Manufacturers of America. He also is the chair of the Product Quality Research Institute Steering Committee and is a member of the PQRI Board of Directors. A native of New York City, he received his BA (cum laude) in chemistry from SUNY at Buffalo in 1972 where he was elected to Phi Beta Kappa, and earned his doctorate in biomedical sciences from the Mt. Sinai School of Medicine (CUNY) in 1978. He has been a Diplomate of the American Board of Toxicology since 1981.

**G. A. (BERT) MITCHELL**  
**Associate Director, Policy and Regulations**  
**Center for Veterinary Medicine**  
**Food and Drug Administration**

Dr. G. A. (Bert) Mitchell served as Director, Health Industries Research at Ralston Purina for 18 years and as the Director of the Bureau of Veterinary Drugs in Canada for 6 years before becoming Director of the Office of Surveillance and Compliance at the FDA, Center for Veterinary Medicine (CVM) in 1988. In 1996, he was made Associate Director of Policy and Regulations and in 1999, he became Acting Deputy Director, Center for Veterinary Medicine. Dr. Mitchell received his D.V.M. degree from the Ontario Veterinary College.

He has been recognized through performance awards from industry and government. He is the recipient of many awards including the McGillivray Award for excellence in leadership as an undergraduate; Supergoal Winner for outstanding achievement over a period of 1,000 days; and Boss of the Year. He was the leader of the team that drafted the BSE regulations. He engaged with the industry and general public to produce the BSE regulations.

**BERNARD A. SCHWETZ, D.V.M., PH.D.**  
**Acting Deputy Commissioner, and Senior Advisor for Science**  
**Food and Drug Administration**

Dr. Schwetz is the Acting Deputy Commissioner of the Food and Drug Administration (FDA) and the Senior Advisor for Science for the agency. He was director of FDA's National Center for Toxicological Research in Jefferson, Arkansas, from 1993 to 1999. A diplomate of the American Board of Toxicology, Dr. Schwetz was acting Director of the Environmental Toxicology Program at the National Institutes of Health's National Institute of Environmental Health Sciences (NIEHS) in Research Triangle Park, NC, before coming to the FDA in 1993. He was also Associate Director of the National Toxicology program there. He had been Chief of the Institute's Systems Toxicity Branch since 1982. Dr. Schwetz currently serves as Adjunct Professor, Department of Pharmacology and Toxicology/Division of Interdisciplinary Toxicology, at the University of Arkansas for Medical Sciences. He was editor, Fundamental and Applied Toxicology from 1986-1992, and serves on the Editorial Advisory Board, Environmental Health Perspectives and Critical Reviews in Toxicology.

Dr. Schwetz is an invited member of the Commonwealth of Canada Health Protection Branch Science Advisory Board, an elected member of the National Academy of Sciences Institute of Medicine, a member of the Society of Toxicology (SOT) and the National Capitol Area Chapter, SOT; the American Veterinary Medical Association; National Society of Phi Zeta, Honor Society of Veterinary Medicine; Teratology Society; Behavioral Teratology Society; and the Reproductive Toxicology Specialty Section of the SOT. He is past president of the Reproductive Toxicology Specialty Section of the SOT and of the North Carolina Chapter and the South Central Chapters of the SOT. In addition to numerous other professional awards during his career, Dr. Schwetz received the U.S. Government's 1998 Meritorious Executive Presidential rank Award.

**LINDA A. SUYDAM, D.P.A.**  
**Senior Associate Commissioner**  
**Food and Drug Administration**

As Senior Associate Commissioner, Dr. Suydam is responsible for the development and implementation of processes to implement change and develop new regulatory strategies for the Food and Drug Administration (FDA) to efficiently and effectively operate within a global economy. Dr. Suydam advises the Commissioner on all matters concerning strategic management and oversees all activities within the Office of the Commissioner. One of her principal responsibilities was the development of the initial Agency plan required under Section 406(b) of the Food and Drug Administration Modernization Act of 1997.

Prior to rejoining the Agency in July 1998, Dr. Suydam was the Associate Vice President for Planning and Development of the Health Sciences Center (HSC) at the University of New Mexico in Albuquerque. The HSC is the only comprehensive patient care, education, and research health care organization in New Mexico. Dr. Suydam was responsible for strategic and facilities planning, marketing, public relations, development, research coordination, the animal research facility and the HSC Library.

Dr. Suydam's career at the FDA prior to 1995 spanned 17 years of more progressive responsibility beginning in the Bureau of Medical Devices as a program analyst and including six years as the executive officer for the Center for Devices and Radiological Health; two years as the Associate Commissioner for Operations in the Office of the Commissioner and culminating as the Interim Deputy Commissioner for Operations from April 1994 until September 1995. During her FDA career, Dr. Suydam received numerous awards including the Department of Health and Human Services Secretary's Award for Distinguished Service, the Public Health Service Superior Service Award, two individual FDA Awards of Merit and many group awards.

Prior to joining the FDA in 1978, Dr. Suydam held progressively responsible professional positions in the public and private sector as a counseling administrator, social work supervisor and caseworker. Dr. Suydam holds a BA from the College of New Jersey, an MA from George Washington University, an MPA from the University of California (USC), and a Doctorate in Public Administration from USC. She is married to Dr. Gerald L. Barkdoll and resides in Rockville, Maryland.

**JANET WOODCOCK, M.D.**  
**Director, Center for Drug Evaluation and Research**  
**Food and Drug Administration**

Janet Woodcock, M.D. is the Director, Center for Drug Evaluation and Research. Prior to this, she was Director, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). Dr. Woodcock is an internist/rheumatologist with research experience in immunology. She joined FDA in 1985. She served as the Director of the Division of Biological Investigational New Drugs in CBER from 1988-1992 and was Acting Deputy Director of the Center in 1991 and 1992. Dr. Woodcock received her M.D. from Northwestern Medical School, and completed further training and held faculty appointments at the Pennsylvania State University and the University of California in San Francisco.

## Collaborating with Stakeholders Registration Form

If you are interested in attending and/or speaking at one of the *FDA Collaborating with Stakeholders* meetings, please fill out the form below.

Title \_\_\_\_\_ First Name \_\_\_\_\_ Last Name \_\_\_\_\_

Organization \_\_\_\_\_ Email \_\_\_\_\_

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Please select the meeting you would like to register for:

- Stanford University, Stanford, California, March 23, 2000.
- Duke University, Durham, N.C., April 12, 2000.

Please indicate below whether you will be presenting comments at the meeting or just attending the meeting.

- I would like to attend the meeting, but not make a presentation.
- I would like to attend the meeting and make a presentation on one or more of the following proposed initiatives. (Please select which initiative(s) your presentation will be on):
  - Safety Assurance in Clinical Trials
  - Gene Therapy, Human Cellular and Tissue Based Products
  - Risk Management
  - Internet
  - NCTR Chip Technology

Please specify if you need special accommodations:

---

Send Forms to:

California: Judy Keast, FDA, Federal Bldg. 1301 Clay St., #1180N, Oakland, CA 94612; Fax: 510-637-3976  
North Carolina: Mary Lewis, FDA, 310 New Bern Ave., #370, Raleigh, NC 27601; Fax: 919-856-4776  
(You may also register via our website at [www.fda.gov/oc/leveraging/stakeholders2000](http://www.fda.gov/oc/leveraging/stakeholders2000))

PREFIX	FIRST NAME	LAST NAME	ORGANIZATION
	Marelle	Molbert	Duke Clinical Research Institute
Ms.	Anna	Robinson	Duke University Medical Center
Mr.	Mark	Senak	Manning Selvage & Lee
Dr.	Elizabeth	DeLong	Duke Clinical Research Institute
Dr.	Kerry	Lee	Duke University Medical Center/Clin. Res. Instit.
Ms.	Lisa	Zimmerman	Duke Clinical Research Institute
Mr.	James	Melton	Duke Clinical Research Institute
Dr.	Ann	Brown	Duke University Medical Center
Dr.	Judith	Kramer	Duke Clinical Research Institute
Ms.	Leanne	Madre	DCRI/Duke University Medical Center
Mrs.	Mae	Burks	Psychiatry(Clinical Trials Office)
Ms.	Mary Ann	Sellers	Duke Clinical Research Institute
Dr.	Hameed	Allaudeen	Duke Clinical Research Institute
Ms.	Beth	Fraulo	DCRI
Mrs.	Shelley	Myles	Duke Clinical Research Institute
Mrs.	Julie	Orr	Duke Clinical Research Institute
	Cynthia	Binanay	Duke Clinical Research Institute
Dr.	L. Kristin	Newby	Duke Clinical Research Institute
Ms.	Deborah	Hilgenberg	Duke Clinical Research Organization
Dr.	Michael	Cuffe	Duke Clinical Research Institute
Mr.	David	Rendall	Duke University
Mrs.	Lois	Rittenhouse	Duke Clinical Research Institute
Ms.	Kathleen	Edwards	Duke Clinical Research Institute
Mr.	Raul	Rojas	May View Community Health Centers
Mr.	Dave	Langley	USDA, Food Safety Inspection Service
Dr.	Charles	Hamner	North Carolina Biotechnology Center
	Alan	Minsk	Arnall Golden & Gregory, LLP
Ms.	Terry	Williams	MoliChem Medicines, Inc.
	Dan	Ragan	NCDA&CS, Food & Drug Protection
Dr.	Pamela	Diliberto	Duke University Medical Center
Ms.	Marilyn	Jansen	GlaxoWellcome
Ms.	Sandy	Kerner	GlaxoWellcome Inc.
Mr.	Kevin	McDonald	PAREXEL International
Ms.	Gail	Glifort	PAREXEL International
Mrs.	Miriam"Bunny"	Donohue	Duke Clinical Research Institute
Dr.	Rose	Fife	Indiana University School of Medicine
Mr.	Christopher	Smith	AAI
Mrs.	Sharon	McGehee	Duke Clinical Research Institute
Dr.	Harry	Guess	Merck Research Laboratories
Dr.	Eric	Peterson	Duke University Medical Center
Dr.	Jerry	Hjelle	Monsanto Company
Ms.	Kimberly	Slade	Duke Clinical Research Institute
Dr.	Julie	Opitech-Carpen	Duke Clinical Research Institute
Dr.	Barry	Mangum	Quintiles, Inc.
Dr.	Judith	Beach	Quintiles Transnational Corp.
Dr.	Cindy	Green	Duke Clinical Research Institute
Mrs.	Cindi	Gardner	Duke Clinical Research Institute
Mr.	James	McAllister	UNC Hospitals

PREFIX	FIRST NAME	LAST NAME	ORGANIZATION
Mrs.	Kimberly	Travis	Duke Clinical Research Institute
	Winston	Liao	Research Triangle Institue
Ms.	Jennifer	Hutchinson	Banner Pharmacaps
Ms.	Barbara	Garlock	Health Data Institute
Ms.	Rosanne	Sylvia-Heeter	Banner Pharmacaps Inc.
Ms.	Celine	Clive	Polaris Clinical Research Consultants, Inc.
Dr.	Robert	Harrington	Duke Clinical Research Institute
Mr.	Ross	Thompson	University of North Carolina Hospitals
Mr.	Phil	Greene	TAB Clinical Trials, Inc.
Mr.	Wayne	Talton	Glaxo Wellcome, Inc.
Mr.	Ron	Sanyal	Oraganon Teknika Corporation
Dr.	Richard	Kiernan	Cloudy Bay Consultants, LLC
Dr.	Kenneth W.	Mahaffey	Duke Clinical Research Institute
Mrs.	Rebecca	Rivas	Oraganon Teknika Corporation
Ms.	Shandrai	Boyd	ClinTrials Research
Mr.	Dan	Garrett	North Carolina Association of Pharmacists
Mr.	William	Harris	Duke University Health Department System
Dr.	Lille	Plumer	Duke University Medical Center
Dr.	John	Kessler	Duke University Medical Center
Mr.	Michael	Woody	NCDA&CS Food & Drig Protection Div
Dr.	John	Falletta	Duke University Medical Center
Dr.	Anthony	Santapolo	Bristol-Myers Squibb
Ms.	Jean	Hurwitz	Duke Pediatric Clinic Research Program
Ms.	Gail	Shulby	Duke University Hospital
Dr.	Rowell	Daniels	UNC Hospitals Department of Pharmacy
	Cheryl	Eckard	Glaxo Wellcome
Dr.	Truls	Ostbye	Department of Community and Family Medicine
Ms.	Julie	Mohr	University of NC School of Pharmacy
Dr.	Suzanne	Cook	Glaxo Wellcome
Dr.	Richard	Drew	Duke Medical Center
	Anne	McKay	Triangle Pharmaceuticals, Inc.
Ms.	Anita	MacMullan	North Carolina Dept. Agriculture & Consumer Se
Ms.	Lisa	Zimmerman	Duke Clinical Research Institute
Ms.	Kathleen	Andrews	Glaxo Wellcome, Inc.
	David M.	Cocchetto, Ph.	Glaxo Wellcome, Inc.
	Mary Ann	Wochlemann	Organon, Inc.
Dr.	Stephanie	Earnshaw	Research Triangle Institue
Mr.	Michael	Dombeck	Research Triangle Institue
Mr.	Elizabeth	Brooks	Research Triangle Institue
Mr.	Michael	Ferrante	ASQ/FDC Division
Dr.	Ronald	Johnson	Research Triangle Institue
Dr.	Patricia	Grossman	Glaxo Wellcome
Ms.	Joyce	Lonergan	Chiron Corporation
Dr.	Jerrold	Levy	Emory University School of Medicine
Dr.	Kevin	Schulman	Duke Clinical Research Institute
Dr.	Susan	Watts	Family Health International
Mrs.	Mary	Sides	Glaxo Wellcome
Dr.	Craig	LaForce	North Carolina Clinical Research

PREFIX	FIRST NAME	LAST NAME	ORGANIZATION
	Anne	McKay	Triangle Pharmaceuticals, Inc.
Mr.	George	Turner	Duke University School of Nursing
Dr.	Michael	Samuhel	Research Triangle Institue
Mr.	Allen	Duffer	Research Triangle Institue
Dr.	Sarah	Sellers	Consultant
	Alison	Bowers	Glaxo Wellcome
Dr.	Alan	Blumberg	Ingenix International
Ms.	Melody	Enscore	ClinTrials Research, Inc.
Dr.	Blythe	Devlin	Synpac (NC), Inc.
	Sandra	Bettenhausen	Glaxo Wellcome
Ms.	Carol	Berman	Glaxo Wellcome Inc.
Ms.	Terry	Crandall	Glaxo Wellcome Inc.
Mrs.	Pat	Gaegler	Glaxo Wellcome Inc.
Dr.	Michael	Shaw	EthicAd
Dr.	Susan	Sisk	Ingenix International Inc.
Dr.	Judith	Beach	Quintiles Transnational Corp.
Dr.	Hugh	Tilson	UNC School of Public Health
Mr.	Stephen	Northrup	Medical Device Manufacturers Association
Dr.	Peter	Kussin	Duke University Medical Center
Dr.	Samuel	Wilson	National Institute of Environmental Health Scien
Dr.	John	Fagan	Genetic ID, Inc.
	Alan	Hanks	AAFCO
Ms.	Mary Rose	Tully	Human Milk Banking Association of North Ameri
Dr.	Elizabeth	Brooks	Research Triangle Institute
Mr.	Holt	Anderson	NC Healthcare Information & Communication All
Dr.	William	McCready	Intersurvy, Inc.
Dr.	Robert	Califf	Duke University
Dr.	Veronica	Scott	Nashville/York Veterans Administration GRECC
Mr.	Doug	Saunders	Association of Food and Drug Officials
Mr.	John	Mack	Internet Healthcare Coalition
Mr.	Michael	Ferrante	ASQ/FDC Division
	Maude	Hinchee	Monsanto
Mrs.	Mercedes	Davila-Owens	ClinTrials Research
Ms.	Carolyn	Poe	ClinTrials Research
Mrs.	Cristy	Burnette	ClinTrials Research
Dr.	M Lynn	Pritchard	Glaxo Wellcome, Inc.
Dr.	Suzanne	West	Research Triangle Institue
Ms.	Lindsay	Lambe	DCRI
Mr.	Joe	Barefoot	Closure Medical Corporation
Dr.	Kenneth	Broda	Duke University Health System
Dr.	Rowena	Dolor	Duke University Medical Center
Dr.	Anthony	Dren	Duke University School of Nursing
Dr.	Ubavka	DeNoble	ClinTrials Research, Inc.
Miss	Deborah	Roth	Duke Clinical Research Institute
Ms.	Lynne	Boone	PPD Development
Dr.	Melissa	King	DUMC
Dr.	George	Cianciolo	Duke University Medical Center

PREFIX	FIRST NAME	LAST NAME	ORGANIZATION
Mr.	Michael	Shiflett	American Labor/LAB ACM Inc.
Ms.	Pamela	Marquard	Marquard Quality Resources
Ms.	Charlotte	Coley	Duke University Medical Center
Dr.	Wajeeh	Bajwa	Duke University Medical Center
Dr.	Sue	Frederick	ClinTrials Research
Dr.	Philippa	Charlton	ClinTrials Research
Dr.	John	Georgitis	Wake Forest University Baptist Medical Center
MD	Russel	Kaufman	Duke University
Ms.	Francine	Lamoriello	Baker Donelson Bearman & Caldwell
Ms.	Denise	Broughton	Buckeye
	Alan R.	Hanks	Office of Indiana St. Chemist, Representing -Ass
Dr.	Heidi	Marchland	Pfizer Inc.
Mr.	Kyle	Nelson	US Surgical
Ms.	Michelle	Usher	PPD Development
Dr.	Loren	Miller	PPD Development
Dr.	Michaelle	Fisher	USDA-Food Safety and Inspections Service (FS
	Thomas	Littlejohn M.D	Peidmont Medical Research
Dr.	Beth	McLendon	Duke Univ. Medical Ctr, Drug Information Center
Dr.	Claude	Drobnes	Triangle Pharmaceuticals, Inc.
	Cuttina	Greene	Triangle Pharmaceuticals, Inc.
Mr.	Don	Howell	NC Dept. of Agriculture & Consumer Services
Mr.	Kurt	Weber	The North Carolina Eye Bank
Mr.	Neil	Petry	Duke University Medical Center
Dr.	Terry	Yoshizumi	Duke University
Dr.	Robert	Reiman	Duke University Medical Center
	Christopher	Granger M.D.	Duke Clinical Research Organization
Dr.	Debbie	Fritz	Glaxo Wellcome
Dr.	Chris	Brown	Dynamic Corporation
Mr.	Drew	Stoudt	Private Consultant
Mr.	David	Jones	Northern Hospital of Surry County
Ms.	Alice	Lenihan	NC Dept of Health and Human Services
Dr.	Hosni	Hassan	NC State University
Dr.	Mary Ann	Lamb	Bayer Corporation
Mr.	Matthew	Lewis	AAC, Inc.
Dr.	Kirk	Adams	University of North Carolina
Dr.	M. Louise	Markert	Duke University Med. Ctr.
Dr.	Johannes	Vieweg	Duke University Medical Center
Mrs.	Doris	Coleman	Duke University Medical Center
Dr.	Michael	Schetzline	Duke University
Mr.	Jeff	Harper	HRF, Inc.
Dr.	Joseph	Farmer	Duke Univ. Med. Center
Dr.	Bruce	Klitzman	Duke University Medical Center
Ms.	Debbie	Travers	University of North Carolina
Dr.	Jeffrey	Lawson	Duke University Medical Center
Ms.	Meg	Neal	Duke University Medical Center
Dr.	Gary	Archer	Duke University
Dr.	John	Sampson	Duke University
Mr.	Paul	Manley	Johnson & Johnson Consumer Products WW

PREFIX	FIRST NAME	LAST NAME	ORGANIZATION
Mrs.	Beverly	Brockschmidt	North Carolina Association of Healthcare Quality
Ms.	Susan	Thomason	Quintiles Transnational Corporation
Dr.	Larry	Kessler	FDA-CDRH-OSB
Mr.	Lee	Evans	SAS Institute
Ms.	Kay	Obenshain	SAS Institute
Dr.	Ed	Helton	SAS Institute
Dr.	Joseph	Moore	Duke University Medical Center
Dr.	Lois	Hoppstein	Clinical TeleHealth
Miss	Aubrey	Betts	Duke University, Office of Federal Relations
Mr.	Edward (Bruce)	Williams	NC Dept. of Agriculture & Consumer Services
Ms.	Laura	Greiner	American Cancer Society
Dr.	Katheryn	Connor	Duke Univ. Medical Center
Dr.	Ranga	Krishnan	Duke University Medical Center
	Joel	Weiner	Health Canada
Dr.	Charles	Hamner	North Carolina Biotechnology Center
Dr.	Wajeeh	Bajwa	Duke University Medical Center
Dr.	Barry	Mangum	Quintiles, Inc.
Mrs.	Cindy	Holeman	Duke Clinical Research Institute
Dr.	Christine	Jenkins	Pfizer Animal Health
	Angela	Hatton	Clintrials Research Inc.
Dr.	George	Waterhouse	Serentec, Inc.
Ms.	Mary	Musacchia	SAS Institute
	Martis	Davis	Burson-Marsteller
	Jeff	Richardson	Burson-Marsteller
Mr.	David	Bridge	Quintiles Transnational
	Alan	Castellion	Global Pharma Associates
Dr.	Paula	Rogenes	Glaxo Wellcome
Dr.	Kathryn	Connor	Duke University Medical Center
Dr.	Ranga	Krishnan	Duke University Medical Center
	Joel	Weiner	Health Canada, Health Protection Branch
Dr.	Bryan	Burlingham	NC AgroMedicare Institute
Ms.	Gwen	Morris	CAS of Cary Inc.
Mr.	Joseph	Freddoso	Cisco Systems, Inc. RTP Campus
Dr.	John	Pitts	Encelle, Inc.
MD.	Elise	Olsen	Duke University Faculty
	Lori	Block	Planned Parenthood
Mr.	Gary	Schrempp	Underwriters Laboratories
Dr.	Alan	Proia	Duke University Medical Center
Mr.	Ed	Helton	SAS Institute Inc.
Ms.	Kay	Obershain	SAS Institute Inc.
	Milton	Bush	The M Companies
Ms.	Kaye	Fendt	Private Consultant
Ms.	Julia	Merricks	Glaxo Wellcome Inc.